Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday,